Back to discover

Protein / target

Replicase polyprotein 1ab

repP0DTD1Severe acute respiratory syndrome coronavirus 2Swiss-Prot
30
Clinical trials
2
Drugs targeting

Protein at a glance

Biological role

MRNA 5'-cap (guanine-N7-)-methyltransferase

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Multifunctional protein involved in the transcription and replication of viral RNAs.

View complete UniProt function annotation

Multifunctional protein involved in the transcription and replication of viral RNAs. Contains the proteinases responsible for the cleavages of the polyprotein

Subcellular location

Host cytoplasmHost endosomeHost endoplasmic reticulum membraneHost Golgi apparatusHost nucleusHost cytoplasm, host perinuclear regionHost endoplasmic reticulumHost endoplasmic reticulum-Golgi intermediate compartment
Domains and Gene Ontology detail (80)

Domains & features

CoV Nsp1 globularBetaCoV Nsp1 C-terminalCoV Nsp2 N-terminalCoV Nsp2 middleCoV Nsp2 C-terminalUbiquitin-like 1Macro 1Macro 2Macro 3DPUPUbiquitin-like 2Peptidase C16Nucleic acid-bindingG2M3EctoCoV Nsp3 Y

Gene Ontology

  • Cdouble membrane vesicle viral factory outer membrane
  • Chost cell endoplasmic reticulum membrane
  • Chost cell endoplasmic reticulum-Golgi intermediate compartment
  • Chost cell endosome
  • Chost cell Golgi apparatus
  • Chost cell nucleus
  • Chost cell perinuclear region of cytoplasm
  • F3'-5'-RNA exonuclease activity
  • F5'-3' DNA helicase activity
  • F5'-3' RNA helicase activity
  • FATP binding
  • FATP hydrolysis activity

7096 aa · 794 kDa · 2 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Transcriptional regulationUniProt · GO · ReactomeProteolysisGOMetabolic enzyme activityGO
View supporting evidence

Transcriptional regulation

  • ·Multifunctional protein involved in the transcription and replication of viral RNAs. Con…
  • ·DNA-templated transcription
  • ·symbiont-mediated suppression of host gene expression
  • ·Assembly of the SARS-CoV-2 Replication-Transcription Complex (RTC)

Proteolysis

  • ·cysteine-type endopeptidase activity
  • ·ISG15-specific peptidase activity
  • ·omega peptidase activity
  • ·proteolysis

Metabolic enzyme activity

  • ·mRNA 5'-cap (guanine-N7-)-methyltransferase activity
  • ·mRNA guanylyltransferase activity
  • ·protein guanylyltransferase activity
View underlying pathways (10)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 4 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Coronavirus Infections1 medicine
COVID-191 medicine
Severe Acute Respiratory Syndrome1 medicine
Virus Diseases1 medicine

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

2

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

remdesivir
Narrow target profileInhibitor

Replicase polyprotein 1ab inhibitor

Indicated for Coronavirus Infections, COVID-19, Severe Acute Respiratory Syndrome, Virus Diseases

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

Azvudine
Narrow target profileInhibitor

Replicase polyprotein 1ab inhibitor

Direct interaction with this protein · 1 of 3 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Label change2026-07-29

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  2. Label change2025-10-07

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  3. Label change2025-08-22

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  4. Label change2025-01-10

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  5. Label change2024-12-19

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  6. Label change2024-06-27

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  7. Indication expanded2024-02-28

    Indication expansion: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  8. Label change2023-08-23

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  9. Label change2023-08-17

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  10. Indication expanded2023-07-13

    Indication expansion: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  11. Label change2023-06-12

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  12. New publication2020-09-01
    Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.

    JAMA · 2020 · 938 citations · Europe PMC · via remdesivir

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.